Title:
SUSTAINED-RELEASE FORMULATION CONTAINING 5-ALPHA REDUCTASE INHIBITOR
Document Type and Number:
WIPO Patent Application WO/2024/019596
Kind Code:
A1
Abstract:
The present invention relates to a sustained-release formulation containing a 5-alpha-reductase inhibitor, and can be used for the prevention, amelioration, or treatment of prostatic hyperplasia and alopecia.
Inventors:
MOON SUNGWOONG (KR)
KIM GEONHO (KR)
SEOL EUNYOUNG (KR)
LEE HEEYONG (KR)
KIM GEONHO (KR)
SEOL EUNYOUNG (KR)
LEE HEEYONG (KR)
Application Number:
PCT/KR2023/010619
Publication Date:
January 25, 2024
Filing Date:
July 21, 2023
Export Citation:
Assignee:
G2GBIO INC (KR)
International Classes:
A61K9/16; A61K9/00; A61K31/58; A61P13/08; A61P17/14
Foreign References:
| CN1965839A | 2007-05-23 | |||
| KR20190132926A | 2019-11-29 | |||
| KR102157124B1 | 2020-09-18 | |||
| KR20190064509A | 2019-06-10 | |||
| CN102133180A | 2011-07-27 |
Other References:
XIE, XIANGYANG ET AL.: "Controlled release of dutasteride from biodegradable microspheres: in vitro and in vivo studies", PLOS ONE, vol. 9, no. 12, 26 December 2014 (2014-12-26), pages 1 - 23, XP055475848, DOI: 10.1371/journal.pone.0114835
Attorney, Agent or Firm:
YOU ME PATENT AND LAW FIRM (KR)
Download PDF: